FIRST WAVE BIOPHARMA ANNOUNCES COMPLETION OF BUSINESS COMBINATION WITH IMMUNOGENX, ADDING PHASE 3-READY LATIGLUTENASE TO ITS LATE-STAGE GI-FOCUSED CLINICAL PIPELINE

Read more

Targeted, Orally Delivered Therapies for Gastrointestinal Diseases

thescience

THE SCIENCE

First Wave BioPharma’s product portfolio is built around its three proprietary therapeutic technologies – latiglutenase, a potentially first-in-class oral biotherapeutic designed to aid gluten digestion and potentially reduce symptoms of celiac disease, capeserod, a selective 5-HT4 receptor partial agonist being developed for gastroparesis, and adrulipase, a recombinant lipase designed to enable the digestion of fats and other nutrients in patients with exocrine pancreatic insufficiency.

LEARN MORE

PIPELINE

First Wave BioPharma’s GI-disease focused programs span multiple clinical indications ranging from nutritional disorders to diseases brought on by autoimmune malfunction. Disease targets include patient populations with digestive disorders, such as celiac disease, gastroparesis, exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis, and inflammatory bowel diseases such as ulcerative colitis.

LEARN MORE

thescience
 
logo ICO

CONTACT

777 Yamato Road
Suite 502
Boca Raton, FL 33431
(561) 589-7020
info@firstwavebio.com

SOCIAL MEDIA

logo ICO

CONTACT

777 Yamato Road
Suite 502
Boca Raton, FL 33431
(561) 589-7020
info@firstwavebio.com

SOCIAL MEDIA